Category - Feature

Feature

CellAegis to complete enrolment in U.S. autoRIC trial by end of 2018

By Len Zehrs In addition to several large ongoing investigator-sponsored studies in Europe and Canada using its autoRIC device for automated remote ischemic conditioning (RIC), closely-held CellAegis Devices expects its...

May 8, 2018

Feature

Aimmune readies filing for FDA approval of peanut allergy treatment

By Len Zehrs On the heels of positive data from its PALISADE pivotal trial, Aimmune Therapeutics (NASDAQ:AIMT) plans to submit a biologics license application with the FDA by the end of 2018 for its peanut allergy...

May 1, 2018

Feature

Cyclica offers Pharma a novel cloud platform to increase R&D productivity

By Len Zehrs During the past four years, closely-held Cyclica has developed and validated a patented structure-based and AI-augmented proteome-screening platform, known as Ligand Express. “The platform enables critical...

April 24, 2018

Feature

Moberg Pharma parlaying topical niche brands to fuel innovation engine

By Len Zehrs Sweden’s Moberg Pharma (OMX:MOB) is focused on maximizing the potential of its market leading position in over-the-counter sales of topical dermatology products to drive development of new therapies for the...

April 17, 2018

Feature

Tear Film Innovations readies launch of iLux device for dry eye disease

By Len Zehrs Closely-held Tear Film Innovations plans to formally launch at two upcoming medical conferences its iLux medical device to treat Meibomian gland dysfunction, the leading cause of dry eye disease. The...

April 10, 2018

Feature

Myomo scaling up distribution of MyoPro robotic arm brace

By Len Zehrs Myomo (NYSE American:MYO) is moving from a controlled introduction over the past few years to a scale up sales and distribution of its MyoPro product line of lightweight, non-invasive, powered arm braces to...

April 3, 2018

Feature

Australia tax incentives spurring R&D

By Len Zehrs Australia is riding a wave of R&D, thanks to generous government tax incentives, as well as the quality of contract research and speed of performing clinical trials. The incentives provide businesses...

March 27, 2018

Feature

Vital Therapies pivotal ELAD trial to read out at end of third quarter

By Len Zehrs Vital Therapies (NASDAQ:VTL) expects to report top line data from its ELAD pivotal study, known as VTL-308, in patients with severe alcoholic hepatitis (sAH), an acute form of liver failure, by the end of...

March 20, 2018

Feature

DarioHealth simplifies diabetes with managed care platform

By Len Zehrs DarioHealth’s (NASDAQ:DRIO) diabetes managed care platform covers all facets of the disease, with a blood glucose device coupled directly to a patient’s smartphone to provide 100% data...

March 13, 2018

Feature

liberDi readies first-in-man study of portable dialysis system

By Len Zehrs Closely-held liberDi plans to initiate in the first half of 2018 the first-in-man clinical trial of its Smart Peritoneal Dialysis System, a small, portable and automatic dialysis device, which is designed...

March 6, 2018

Category - Feature

CellAegis to complete enrolment in U.S. autoRIC trial by end of 2018

Aimmune readies filing for FDA approval of peanut allergy treatment

Cyclica offers Pharma a novel cloud platform to increase R&D productivity

Moberg Pharma parlaying topical niche brands to fuel innovation engine

Tear Film Innovations readies launch of iLux device for dry eye disease

Myomo scaling up distribution of MyoPro robotic arm brace

Australia tax incentives spurring R&D

Vital Therapies pivotal ELAD trial to read out at end of third quarter

DarioHealth simplifies diabetes with managed care platform

liberDi readies first-in-man study of portable dialysis system

General

More